Clinical Trials for Liver Cancer

Study of Intratumoral Injection of Dendritic Cells After High-Dose Conformal External Beam Radiotherapy in Patients With Unresectable Liver Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable primary liver cancer confined to the liver (ECOG 0–1) receive high-dose conformal EBRT followed by intratumoral autologous dendritic cell injections (with intramuscular Prevnar as an immune adjuvant); tumors must be accessible for ultrasound-guided injection. The HCC cohort also adds atezolizumab (anti–PD‑L1) plus bevacizumab (anti‑VEGF) to the DC/EBRT regimen.

ClinicalTrials.gov ID: NCT03942328

A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors and ECOG 0–2, including a cohort with moderate hepatic impairment (bilirubin >1.5×–≤3× ULN), receive sacituzumab govitecan-hziy (Trop-2–targeted ADC delivering SN-38) on Days 1 and 8; dose-escalation (5→7.5→10 mg/kg) is tested in the impaired-liver cohort with a normal-liver comparator at 10 mg/kg. Excludes recent irinotecan, active CNS disease, Gilbert’s syndrome, strong UGT1A1 modulators, and significant liver-related complications in the impaired cohort.

ClinicalTrials.gov ID: NCT04617522

A Phase 1 Study of Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable hepatocellular carcinoma or liver-only metastases receive Y-90 radioembolization (TheraSphere) followed by PET-CT–guided SBRT boost to underdosed tumor regions, with strict liver function and no progressive extrahepatic disease required. Aims to assess hepatic decompensation risk and early local control using adaptive dosimetry.

ClinicalTrials.gov ID: NCT04518748

Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced, GPC3-positive hepatocellular carcinoma (≥25% by IHC) who have progressed on or are intolerant to first-line therapy receive lymphodepleting fludarabine/cyclophosphamide followed by a single infusion of autologous GPC3-targeted CAR-T cells (humanized anti-GPC3 hYP7) that recognize glypican-3 to mediate tumor cell killing. Key exclusions include Child-Pugh B/C and uncontrolled comorbidities; controlled HBV/HCV and stable treated brain metastases are allowed.

ClinicalTrials.gov ID: NCT05003895

A Phase 1, Open-label, Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors and either moderate hepatic impairment or normal liver function receive IV nab-sirolimus (albumin-bound sirolimus, an mTORC1 inhibitor) on Days 1 and 8 of 21-day cycles. The study evaluates safety and pharmacokinetics to define the appropriate dose for patients with moderate hepatic impairment.

ClinicalTrials.gov ID: NCT05661461

A Phase I Dose-Escalation Trial of vvDD-hIL2-2-RG-1 (Vaccina Virus Double Deleted) Administered by Intra-tumoral (IT) Injection for Metastatic Gastrointestinal and Peritoneal Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults <70 with metastatic gastrointestinal or peritoneal tumors (esophageal, gastric, colorectal, liver, pancreatic) refractory to standard therapy, with at least one lesion amenable to intratumoral injection. Single intratumoral dose of vvDD-hIL2-2-RG-1, an oncolytic vaccinia virus (double-deleted TK/VGF) engineered to express membrane-tethered IL-2 to promote localized T-cell activation and oncolysis; no combination therapy in this first-in-human, single-dose escalation.

ClinicalTrials.gov ID: NCT07001592

A Phase I Study of SBRT Vaccination With Atezolizumab and Bevacizumab for Patients With Advanced Hepatocellular Carcinoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable/ablation-ineligible advanced hepatocellular carcinoma requiring systemic therapy receive concurrent stereotactic body radiotherapy (escalating doses) plus atezolizumab (anti–PD-L1) and bevacizumab (anti-VEGF). Designed to assess safety and preliminary efficacy of the triplet and define the SBRT dose to combine with this standard immunotherapy/anti-angiogenic regimen.

ClinicalTrials.gov ID: NCT05488522

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic solid tumors involving lung and/or liver (≥2 measurable lesions; prior PD-1/PD-L1 allowed) receive intratumoral NBTXR3 (hafnium oxide radioenhancer nanoparticles) injected into a lung or liver lesion plus anti–PD-1/PD-L1 therapy, randomized to either high-dose RT to one lesion only (abscopal) or high-dose RT to one lesion plus low-dose RT to additional lesions (RadScopal). Excludes prior RT to the high-dose target lesion, uncontrolled CNS disease, significant unresolved irAEs/radiation toxicities, active autoimmune disease requiring systemic therapy, and uncontrolled infections.

ClinicalTrials.gov ID: NCT05039632

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors (ECOG 0–1) receive IV TORL-4-500 monotherapy every 3 weeks; TORL-4-500 is a DLK1-targeted antibody–drug conjugate (humanized anti-DLK1 IgG1 linked to MMAE via a val-cit linker) intended for DLK1-expressing tumors. Key exclusions include uncontrolled/symptomatic brain mets, significant cardiac disease, active infections, unresolved prior toxicities, and recent other malignancies.

ClinicalTrials.gov ID: NCT06005740

A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic HCC (Child-Pugh A–B7) after ≥1 prior systemic therapy and harboring a WNT-pathway–activating alteration receive ALN-BCAT, an IV siRNA that silences CTNNB1 (β-catenin) via hepatic LNP delivery, as monotherapy or combined with pembrolizumab. Excludes fibrolamellar/sarcomatoid/mixed cholangio-HCC and symptomatic extrahepatic disease; aims to define dose and assess preliminary activity, with the combo exploring β-catenin suppression to enhance PD-1 response.

ClinicalTrials.gov ID: NCT06600321